Alicyn Magruder, PharmD, BCACP, MSCS

Clinical Pharmacist at Mizzou Specialty Pharmacy within the Neurology and Sleep Disorders Clinic

Articles by Alicyn Magruder, PharmD, BCACP, MSCS

Looking Ahead at MS Treatment and Closing Thoughts on Biosimilars

ByJeffrey Cohen, MD,Sarah Anderson, PharmD, NBC-HWC,Alicyn Magruder, PharmD, BCACP, MSCS,Matt Hoffman

October 31st 2023

Jeffrey Cohen, MD; Sarah Anderson, PharmD, NBC-HWC; and Alicyn Magruder, PharmD, BCACP, MSCS, share their final thoughts on the future landscape of clinical MS care in the biosimiliars era. [WATCH TIME: 12 minutes]

Resources on MS Biosimilars for Patients and Clinicians

ByJeffrey Cohen, MD,Sarah Anderson, PharmD, NBC-HWC,Alicyn Magruder, PharmD, BCACP, MSCS,Matt Hoffman

October 29th 2023

The group continues discussion about patient communication needs, and Sarah Anderson, PharmD, shares resources that the National MS Society offers to both patients and providers. [WATCH TIME: 9 minutes]

Navigating the Switch From Brand Name to Biosmilar Products With Patients

ByJeffrey Cohen, MD,Sarah Anderson, PharmD, NBC-HWC,Alicyn Magruder, PharmD, BCACP, MSCS,Matt Hoffman

October 27th 2023

Jeff Cohen, MD, and Alicyn Magruder, PharmD, BCACP, MSCS, discuss the best practices when switching to a biosimilar therapy, including patient education and when to consider an insurance appeal. [WATCH TIME: 7 minutes]

The Pharmacist Perspective on MS Biosimilars and the Possible Monitoring Needs

ByJeffrey Cohen, MD,Sarah Anderson, PharmD, NBC-HWC,Alicyn Magruder, PharmD, BCACP, MSCS,Matt Hoffman

October 25th 2023

Alicyn Magruder, PharmD, BCACP, MSCS, offers insight into the pharmacist's role in patient education on biosimilars for MS, and the group discusses the potential need for a long-term monitoring system. [WATCH TIME: 10 minutes]

The MS Landscape and Historical Use of Off-Label Biosimilars

ByJeffrey Cohen, MD,Sarah Anderson, PharmD, NBC-HWC,Alicyn Magruder, PharmD, BCACP, MSCS,Matt Hoffman

October 23rd 2023

A group of panelists set the stage for the introduction of biosimilar therapies in multiple sclerosis care, and offer an overview of the current landscape of treatment. [WATCH TIME: 9 minutes]